| Literature DB >> 34674861 |
Vasilis C Babaliaros1, Robert J Lederman2, Patrick T Gleason3, Jaffar M Khan2, Keshav Kohli4, Anurag Sahu5, Toby Rogers6, Christopher G Bruce2, Gaetono Paone3, Joe X Xie3, Norihiko Kamioka7, Jose F Condado8, Isida Byku3, Emily Perdoncin3, John C Lisko3, Adam B Greenbaum3.
Abstract
The SAPIEN 3 is the only transcatheter heart valve commercially available for compassionate transcatheter mitral valve replacement in patients with previous mitral surgical rings and mitral annular calcification (valve in ring [VIR] and valve in mitral annular calcification [VIM]). Reported outcomes have been inconsistent or poor. The review provides an overview of the authors' approach to achieve largely consistent results despite the intrinsic limitations of SAPIEN 3 VIM and VIR. The approach includes bedside modifications of the valve implant, the delivery system, and of the cardiac substrate itself. Until purpose-built devices are readily available, VIR and VIM procedures will require aggressive multidisciplinary cooperation, meticulous planning and execution, and postprocedure management by experienced, high-volume operators.Entities:
Keywords: LAMPOON; SAPIEN 3; mitral annular calcification; transcatheter electrosurgery; transcatheter mitral valve replacement; valve-in-ring
Mesh:
Year: 2021 PMID: 34674861 PMCID: PMC8978536 DOI: 10.1016/j.jcin.2021.08.044
Source DB: PubMed Journal: JACC Cardiovasc Interv ISSN: 1936-8798 Impact factor: 11.195